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Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) can be caused by mutations in the
neuronal nicotinic acetylcholine receptor (nAChR) subunit genes CHRNA4 and CHRNB2. Recently, a
point mutation (a2-I279N) associated with sleep-related epilepsy has been described in a third
nAChR gene, CHRNA2. We demonstrate here that a2-I279N can be co-expressed with the major
structural subunit CHRNB2. a2-I279N causes a marked gain-of-function effect and displays a distinct
biopharmacological proﬁle, including markedly reduced inhibition by carbamazepine and increased
nicotine sensitivity.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
was the ﬁrst idiopathic epilepsy in humans that could be success-
fully linked to speciﬁc mutations. Mutations in two genes are
known to cause ADNFLE, CHRNA4 and CHRNB2 encoding the a4
and b2 subunits of the neuronal nicotinic acetylcholine receptor
(nAChR), respectively [1,2]. Recently, in a single family a missense
mutation was found in a third nAChR gene, CHRNA2 on chromo-
some 8p21 [3]. The mutation a2-I279N (numbering according to
reference sequence NP_000733) (Fig. 1) is associated with sleep-
related epilepsy, ictal fear and nocturnal wandering. Two inde-
pendent follow-up studies were not able to identify additional
CHRNA2 mutations in larger samples of ADNFLE families [4,5].
Thus it is still unclear if the clinical phenotype caused by a2-
I279N mutations should be termed ADNFLE or if it is a new type
of sleep-related epilepsy. To get a better understanding of the
functional impact associated with a2-I279N on receptor level it
would therefore be interesting to compare the functional charac-
teristics of a2-I279N with those of known ADNFLE mutations onchemical Societies. Published by E
turnal frontal lobe epilepsy;
erase chain reaction; Ach,
en.de (O.K. Steinlein).a molecular level. Most neuronal nAChR a subunits need to be co-
expressed with one of the three b subunits (b2–b4) to build func-
tional receptors. So far, a2-I279N has only been characterized in
combination with the structural b4 subunit (a2-I279Nb4) [3],
which has a very restricted expression pattern in primate brain
and is therefore not a plausible candidate for the main in vivo
partner of a2. Most functional studies of known ADNFLE muta-
tions used the ubiquitously expressed a4b2 nAChR, which makes
it difﬁcult to compare the electrophysiological and pharmacoge-
netic proﬁles of ‘‘classical” ADNFLE mutations with a2-I279N.
To address this issue further we have therefore co-expressed
a2-I279N with the major structural nAChR subunit, b2, and ana-
lyzed the heteromeric a2-I279Nb2 receptor with respect to its
functional properties, agonist response, nicotine effects and sensi-
tivity towards carbamazepine, an antiepileptic drug frequently
used for the treatment of frontal lobe seizures.
2. Materials and methods
2.1. Mutation construct
CHRNA2 cDNA was PCR-ampliﬁed from a commercially avail-
able human brain cDNA panel (QUICK-CloneTM cDNA human brain,
thalamus (Clontech)) using sequence speciﬁc primers (sequences
available on request) with overhangs introducing cleavage sites
for the restriction endonucleases SpeI and EcoRI. After restrictionlsevier B.V. All rights reserved.
Fig. 1. Mutation I279N is located in the ﬁrst transmembrane domain of CHRNA2. (A) Alignments of the amino acid sequences of a series of a and b nAChR subunits illustrate
the high degree of conservation observed in the 279 residue and the uniqueness of the point mutation I279N. (B) Putative structure of the nAChR and position of the mutation
I279N. This structure is based on high-resolution electron microscopy [17] and protein homology model [18].
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vector pTracerTMEF/V5-His (Invitrogen). The sequence was veriﬁed
to correspond to GenBank accession number NM_000742 by direct
sequencing. The expression plasmid for CHRNB2 was obtained by
cloning the CHRNB2 cDNA (sequence corresponding to
NM_000748) into the restriction sites KpnI and NotI of plasmid vec-
tor pTracer. The sequence was also conﬁrmed by direct sequencing.
We introduced the CHRNA2 mutation I279N [3] using PCR-based
site-directed mutagenesis (QuikChange II site-directed mutagene-
sis Kit (Stratagene)). Mutagenesis was performed according to
the manufacturers instruction using primers t836a (50-
ccctgcctgctcaactcctgcctcact-30) and t836a-as (50-agtgaggcaggagtt-
gagcaggcaggg-30). The presence of the introduced mutation was
conﬁrmed by direct sequencing.
2.2. Oocyte expression
Oocytes were isolated and selected as previously described [6].
Brieﬂy, oocytes were harvested from mature Xenopus females fol-
lowing animal ethic rules of Geneva canton, Switzerland. Oocytes
were isolated by mechanical and enzymatic action using type I col-
lagenase (Sigma, Basel Switzerland) at 0.2% in a medium deprived
of calcium. Stage V and VI oocytes were placed in 96 wells micro-
titer plates (NUNC) in BARTH medium that contained 88 mM NaCl,
1 mM KCl, 2.4 mMNaHCO3, 10 mMHEPES, 0.82 mMMgSO4  7H2O,
0.33 mM Ca(NO3)2  4H2O, 0.41 mM CaCl2  6H2O, adjusted to pH
7.4 with NaOH and complemented with kanamycin (20 mg/ml),
penicillin (100 U/ml) and streptomycin (100 U/ml). Nuclear injec-
tions of 2 ng of cDNAs containing in equal ratios the genes of inter-
est were performed with an automate [7], and cells were
subsequently maintained at 18 C.
2.3. Recording of nAChR properties
Electrophysiological properties of oocytes were determined 2–5
days later with a home made automated two electrode voltage
clamp. Oocytes were continuously superfused with OR2 (control
medium) that contained 82.5 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl2,
1 mM MgCl2, 5 mM HEPES, adjusted to pH 7.4 with NaOH. Data
were ﬁltered at 10 Hz and digitized at 100 Hz with an analog to
digital converter (National Instrument) and stored on a personal
computer. Data acquisition, treatment and statistics were per-
formed using Matlab (MathWorks Inc.).2.4. Curve ﬁtting
Concentration–activation curves were ﬁtted using a Hill equa-
tion in the form:
Y ¼ 1=1þ ðEC50=xÞ^nH ð1Þ
where Y is the fraction of evoked current, EC50 is the concentration
for 50% activation of the high afﬁnity, nH is the apparent cooperativ-
ity for the high afﬁnity, and x is the agonist concentration.
Concentration–inhibition curves are ﬁt with a comparable
equation:
Y ¼ 1=1þ ðx=IC50=xÞ^nH ð2Þ
where Y is the fraction of remaining current, IC50 is the concentra-
tion for 50% inhibition, nH is the apparent cooperativity, and x is the
antagonist concentration. For statistical analysis the unpaired, two-
tailed Student’s t-test was computed either with Excel (Microsoft)
or Matlab (MathWorks Inc.).3. Results
The mutation I279N reported by Aridon et al. [3], is located in
the third transmembrane segment of the a2 subunit, as shown in
Fig. 1. Notable is the high degree of sequence homologies for this
protein segment observed both intra- and interspecies. Sequence
alignment of the known neuronal human a subunits further illus-
trates the high degree of conservation of this particular amino acid,
which is substituted by another amino acid only in a5 and b4 sub-
units (Fig. 1A). Moreover, it is noteworthy to observe that this
mutation is in juxtaposition with the leucine L247 (Torpedo num-
bering) in the second transmembrane domain (Fig. 1B). Amino acid
residue position 247 was shown to be critical for the gating of the
desensitized state [8].
3.1. Functional properties of a2I279N/b2
The experiments were carried out by co-expressing either the
wild-type a2 and b2 subunit or the a2-I279N subunit in equal
amounts together with the b2 subunit (referred to as mutant
or a2-I279Nb2). Brief exposure to acetylcholine (ACh) triggered
a typical robust inward current in the lA range indicating that
oocytes readily expressed the human a2b2 combination
Fig. 2. Increased ACh sensitivity caused by mutations in the a2 subunit. (A) Typical responses evoked by brief ACh test pulses applied in increasing concentrations in the
wild-type a2b2 and mutated a2I279Nb2. (B) Comparison of typical currents evoked under similar conditions (30 lM ACh) illustrates the differences in ACh sensitivity. (C)
Semi-logarithmic plot of the peak current as a function of the agonist concentration. Bars indicate the standard deviations observed for a number of cells (n = 7 for both a2b2
and a2I279Nb2). Best ﬁts were obtained with the following values: EC50’s = 80 lM, 0.2 lM for the a2b2 and a2I279Nb2, and nH of 0.9 and 0.82, respectively. The presence of
the point mutation in the ﬁrst transmembrane segment causes a signiﬁcant increase in sensitivity without noticeable changes in the response time course.
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logarithm of the ACh concentration yielded concentration–acti-
vation curves that are well described by the empirical Hill equa-
tion. Data obtained for the wild-type a2b2 are shown by open
squares in Fig. 2C and the dashed line represents the best ﬁt ob-
tained for this data set. Co-expression of a2-I279N with the b2
subunit also yielded high levels of receptor expression as seen
from the large ACh-evoked currents such as illustrated in
Fig. 2. A marked difference is, however, observed on the concen-
tration–activation curve with a left shift indicating that presence
of this mutation causes an increase in ACh sensitivity by a mag-
nitude of a hundred.
3.2. Altered effective nicotine current
To evaluate the activity of nicotine at the a2b2 and a2-I279Nb2
concentration–activation and concentration–inhibition curves
were established. Concentration–activation curves were deter-
mined as previously described by brief exposure to nicotine ap-
plied in growing order [6]. Typical nicotine-evoked currents
recorded in oocytes expressing either the a2b2 or a2-I279Nb2
are shown in Fig. 3A and C. Nicotine concentration–activation
curves show, as for ACh, an important increase in sensitivity after
introduction of the mutation I279N. To determine the concentra-
tion–inhibition curves, the ACh-evoked currents were ﬁrst re-
corded in wild type and mutant receptors in standard medium
with brief ACh test pulses applied once every two minutes using
a concentration approximating the EC50 (5 and 100 lM for the
a2b2 and mutant receptor, respectively). Subsequently, currentsevoked by the same ACh pulses were recorded in the presence of
low, but sustained concentrations of nicotine. Typical currents re-
corded in the wild type and mutant receptors using such protocol
are shown in Fig. 3B and D. Plot of the peak nicotine-evoked cur-
rent as a function of the low and sustained nicotine concentration
yields the concentration–inhibition curve plotted in Fig. 3E. Lines
are the best-ﬁtted regression curves obtained from the Hill equa-
tion (see Section 2). The a2-I279Nb2 receptor displays a dose-
dependent sensitivity to nicotine that is markedly higher than in
the wild type. Effective desensitization, however, is only observed
with nicotine concentrations of 30 nM or more but rather absent at
lower concentrations.
3.3. Carbamazepine sensitivity
The sensitivity of both the a2b2 and a2-I279Nb2 receptors to
the tricyclic molecule carbamazepine was determined. Concentra-
tion–inhibition curves were determined by measuring the ampli-
tude of current evoked by a ﬁxed ACh test pulse (5 and 100 lM,
for the wild type and mutant receptors with 5 s duration) in ab-
sence or presence of increasing concentrations of carbamazepine.
Typical currents obtained for the wild type and mutant receptors
in presence of different concentrations of carbamazepine are
shown in Fig. 4A and B. Plot of the peak currents as a function of
the logarithm of the carbamazepine concentration yielded concen-
tration–inhibition curves shown in Fig. 4C. These data illustrate
that mutation I279N causes a signiﬁcant reduction of the blockade
caused by carbamazepine with an increase in the steepness of the
inhibition curve.
Fig. 3. Nicotine activates and desensitizes the a2b2 and a2I279Nb2 receptors Nicotine-dependent activation and desensitization proﬁles are illustrated for the a2b2 and
mutant a2I279Nb2 receptor subtypes. (A, C) Representative currents evoked by brief applications of increasing nicotine concentrations (0.03, 0.1, 0.3, 1, 3, 10, 30 and
100 lM). Markers above the currents indicate the timing of the applications. (B, D) Desensitization of the receptor caused by sustained nicotine exposure (trace). Nicotine was
gradually increased at each application, as indicated by gray bars above the traces (0, 1, 3, 10, 30, 100, 300 nM). The ACh test pulses were of 100 lM and 5 lM, respectively, for
the a2b2 and the mutant a2I279Nb2. (E) Nicotine concentration–activation curve overlaps with the desensitization curve caused by sustained nicotine exposure. Peak inward
currents were plotted as a function of the agonist concentration. Nicotine-evoked currents (A, C) yielded the activation curves whereas desensitization caused by nicotine
(B, D) yielded the inhibition curves (left). Bars indicate the respective standard error of mean obtained on 5–10 cells. Error bars smaller than the symbol size were omitted for
clarity. Best ﬁts were obtained with the following parameters for the activation: EC50’s = 14 lM and 0.2 lM for a2b2 and a2I279Nb2 with respective nH = 1.4 and 1.2 (n > 9).
For the inhibition best ﬁts were obtained with the following parameters: IC50’s = 8 and 15 nM for a2b2 and aI-279Nb2 with respective nH = 0.7 and 0.8 (n > 9).
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Many neuronal nAChRs are heteromeric pentamers composed
of a subunits and b subunits that can differ with respect to their
expression patterns. Both the a4 and a2 subunit are widely ex-
pressed in mammalian brain [9], and the b2 subunit, which from
all three b-subunits shows the most widespread expression in
brain, is the most likely candidate for an in vivo partner of the mu-
tated subunit a2-I279N. The a2-I279Nb2 receptor can be used to
model the possible key pathomechanisms that start the chain of
events, which ﬁnally leads to uncontrolled neuronal hyperexcit-
ability. Co-expression experiments of a2-I279N with the b4 sub-
unit suggested that the new mutation has a gain-of-function
effect [3]. The data presented here demonstrate that this effect is
not only shared by but is even stronger in the a2-I279Nb2 receptor
subtype. Compared to the wild-type subunits, the co-injection of
I279N-CHRNA2 and CHRNB2 cDNA’s resulted in a signiﬁcantly
higher number of cells that expressed nAChRs on their surface.
The reason for these differences is not known yet; on the RNA level
possible mechanisms include an increase of transcription or trans-
lation rate or RNA stabilization by the mutation. On the protein le-
vel the mutation could hypothetically promote subunit assembly,
improve trafﬁcking or prolong surface expression of nAChRs. The
mutated a2-I279Nb2 receptor also yielded markedly higher ACh-
evoked currents and an increased sensitivity for ACh that exceeded
those seen for the wild-type a2b2 receptor by a factor of more than
10. Such a pronounced activity of a2-I279Nb2 nAChRs would re-
sult in a gain-of-function effect typical for all known ADNFLE
mutations [6,10,11].
The known ADNFLE mutations display striking differences with
respect to their biopharmacological proﬁles. These differences arebest demonstrated for carbamazepine, an antiepileptic drug that
apparently acts as an open channel blocker [12]. Mutations a4-
S280F (numbering according to reference sequence NP_000735.1,
this mutation was previously named a4-S248F [1]), a4-
L289_L290insL (previously named a4-776ins3) [13] and b2-
V287M have shown to markedly increase the nAChRs sensitivity
to carbamazepine [12,14,15]. In patients, carbamazepine can be
expected to counterbalance the gain-of-function effect caused by
these mutations by preferentially blocking mutated receptors. This
would explain why in ADNFLE patients with these mutations the
seizures often can be readily controlled or even prevented by car-
bamazepine, making it the drug of ﬁrst choice. Another ADNFLE
mutation, a4-T293I, does not change the receptors carbamazepine
sensitivity if compared to the wild type [10], while the ADNFLE
mutation a4-S284L decreases rather than increases the receptors
sensitivity towards carbamazepine [12]. Compared to the above-
mentioned mutations a4-S280F, a4-L289_L290insL and b2-
V287M, receptors with either a4-T293I or a4S284L are less likely
to be blocked by carbamazepine. In accordance with these experi-
mental data ADNFLE patients carrying one of the latter mutations
are often not seizure free when treated with this drug in mono-
therapy. Our data demonstrate that the new mutation a2-I279N
also displays its private biopharmacological proﬁle. While the
wild-type receptor shows a dose-dependent increase in carbamaz-
epine sensitivity, the a2-I279Nb2 receptor is not affected by doses
up to 20 lM. The blocking effect is only observed with doses of
40 lM and more, suggesting that carbamazepine is not the ﬁrst
choice antiepileptic drug for treating patients with this mutation.
So far it is not known why the carbamazepine sensitivity pro-
ﬁles of the known nAChR mutations differ so noticeable [13]. An
obvious explanation would be that the affected amino acid
Fig. 4. Carbamazepine inhibition of the a2b2 and mutant receptor. (A, B) Typical ACh-evoked currents recorded in presence of increasing concentrations of carbamazepine
(10, 20, 40, 80, 160 lM). Carbamazepine incubations are indicated by the gray bars above the traces, while small dark bars indicate the timing of the ACh application. (C)
Semi-logarithmic plot of the peak inward current as a function of the carbamazepine concentration yielded typical concentration–inhibition curves that were ﬁtted with the
Hill equation (see Section 2). Values obtained for the best ﬁts were IC50 = 15.4 lM, nH = 0.8 for the wild-type a2b2 receptor and IC50 = 36.6 lM, nH = 2 for the mutant
a2I279Nb2. Error bars indicate the standard error of the mean obtained for n = 6 and 8 cells, respectively. Error bars were omitted when smaller than the symbol size.
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sional receptor structure. However, both S280 and S284 residues
are located close together and are thought to be both exposed to
the lumen in the ion pore’s inner part. These amino acid residues
are likely to have direct contact with an open channel blocker such
as carbamazepine, but still differ in their sensitivity proﬁles. Muta-
tions a4-L289_L290insL, a4-T293I, b2-V287M and the new muta-
tion a2-I279N are either located close to the outer ring of TM2
or in transmembrane regions that are not part of the ion channels
inner wall. These mutations are unlikely to come into direct con-
tact with carbamazepine molecules, but nevertheless show differ-
ences in their responses to carbamazepine both in an experimental
setup and in therapy. Hence the mechanism underlying nAChR
blockade by carbamazepine has to be more complex than previ-
ously assumed.
Nicotine is a natural alkaloid that is known as a powerful ago-
nist for nAChRs. It has already been shown that the biopharmaco-
logical proﬁles of ADNFLE mutations differ with respect to nicotine,
and that only some mutations exhibit the same gain-of-function
effect with nicotine as with ACh. For example, the effective nico-
tinic current of mutants b2-L301V and b2-V308A was slightly
shifted towards higher concentrations, but shifted towards lower
nicotine concentrations with mutant b2-V287M, as compared to
the wild-type receptor [6]. This might have interesting implica-
tions for smoking habits of ADNFLE patients and new treatment
strategies. A pilot study already indicated that nicotine might have
an anticonvulsant effect in ADNFLE patients, at least in those carry-
ing one of the a4 subunit mutations S248F or 776ins3 [16]. It is
tempting to speculate that such an anticonvulsant effect of nico-
tine might not be found in patients carrying mutations such as
b2-L301V and b2-V308A that decrease rather than increase the
effective nicotine current. The a2-I279N mutation displayed a
marked increase in nicotine sensitivity, comparable to that seenfor ACh. Desensitization was only pronounced with higher nicotine
concentrations, resulting in an effective nicotine current that was
signiﬁcantly larger than in the wild type. Thus in patients with this
mutation nicotine might not act as an anticonvulsant but might
even increase the seizure frequency by pronouncing the gain-of-
function effect of a2-I279N.
Taken together, our functional studies demonstrate that the a2
subunit is able to build functional nAChRs with b2 as a partner sub-
unit, and that the a2-I279N mutation drastically changes the elec-
trophysiological and pharmacological proﬁle of this nAChR
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